Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Patrick Northup, MD
Modality
UNKNOWN
Development Phase
N/A
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02123576CT.gov Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatorenal Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pentoxyfylline (this asset) | Patrick Northup, MD | N/A | D · 30 |
| Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide) | Noorik Biopharmaceuticals AG | P4 | A |
| Normal Human Serum Albumin | Massachusetts General Hospital | P4 | BBB |
| Norfloxacin | Hospital Clinic of Barcelona | P4 | BB |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | University of California, Los Angeles | P2/3 | BB |
| Midodrine | University of California, Los Angeles | P2/3 | BB |
| [Phe^2,Ile^3,Dab(Phac-D-Tyr(Me)-Phe-Gln-Asn-Ala-Pro-Arg-Igln-Lys(Ac)-Epsilon-Lys)^8]Vasopressin | Ocelot Bio, Inc | P2 | B |
| Angiotensin Ii | University of California, Los Angeles | P2 | CCC |
| Ambrisentan | Noorik Biopharmaceuticals AG | P2 | CC |
+2 more in the Hepatorenal Syndrome cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide)Noorik Biopharmaceuticals AGA
- Normal Human Serum AlbuminMassachusetts General HospitalBBB
- NorfloxacinHospital Clinic of BarcelonaBB
- L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-University of California, Los AngelesBB
- MidodrineUniversity of California, Los AngelesBB
Citation
Floatz Terminal. Pentoxyfylline in Hepatorenal Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pentoxyfylline-hepatorenal-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →